Dr. Socinski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2501 N Orange Ave
Ste 689
Orlando, FL 32804Phone+1 407-303-2024Fax+1 407-303-2038- Is this information wrong?
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1986 - 1989
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1984 - 1986
- University of Vermont College of MedicineClass of 1984
Certifications & Licensure
- FL State Medical License 2016 - 2026
- NC State Medical License 1995 - 2017
- PA State Medical License 2011 - 2016
- VT State Medical License 1988 - 1996
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
Clinical Trials
- Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2000 Apr 01
- BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment Start of enrollment: 2000 Nov 01
- Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer Start of enrollment: 2005 May 31
- Join now to see all
Publications & Presentations
PubMed
- A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical ...Lee X Li, Ganessan Kichenadasse, Christos S Karapetis, Adel Shahnam, Ross A McKinnon, Andrew Rowland, Ashley M Hopkins, Michael J Sorich, Mark A Socinski> ;BMC Cancer. 2024 Mar 25
- A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Ea...Wang, H., Shaverdashvili, K., Reyes, V., Mehta, D., Marsh, C., Waas, J., VanderWeele, R., Peracha, S., Liang, H., Socinski, M., Gerber, D., Dowell, J., Villaruz, L.> ;Eclinicalmedicine. 2023 Dec 1
- 1 citationsPopulation Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin) in Patients with Non-squamous Non-small Cell Lung Cancer.Joel S Owen, Russell J Rackley, Matthew A Hummel, Stefan Roepcke, Hannah Huang, Mark Liu, Tazeen A Idris, Sundara Moorthi Nainar Murugesan, Ashwani Marwah, Subramanian...> ;European Journal of Drug Metabolism and Pharmacokinetics. 2023 Nov 1
- Join now to see all
Journal Articles
- Predictive Biomarkers for Response to EGFR-Directed Monoclonal Antibodies for Advanced Squamous Cell Lung CancerD R Spigel, E S Kim, S S Ramalingam, M A Socinski, C Obasaju, C J Langer, R B Natale, P D Bonomi, H Wakelee, Annals of Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCRobert M Jotte, Mark A Socinski, The New England Journal of Medicine
- PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung CancerLiza C Villaruz, Mark A Socinski, Molecular Diagnosis & Therapy
Lectures
- IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets).2019 ASCO Annual Meeting - 6/1/2019
- A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) bevacizumab (bev) vs chemo + bev in 1L nonsquamou...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Join now to see all
Press Mentions
- Low-Grade Immune-Related Adverse Events Linked to Prolonged Survival in NSCLCJune 5th, 2021
- AdventHealth Central Florida Asks for 40K Vaccines from State, Gets 500February 4th, 2021
- AdventHealth Sees Number of Hospitalized Patients DropFebruary 4th, 2021
- Join now to see all
Grant Support
- Trial Of Escalating Dose Paclitaxel In Patient With Refractory Solid TumorsNational Center For Research Resources1997–1999
Professional Memberships
- Member
Hospital Affiliations
- AdventHealth OrlandoOrlando, Florida
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: